# GRCE (Grace Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Grace Therapeutics, Inc. reported $57.70M in total assets and a net loss of $21.41M through March 31, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/GRCE
- Markdown: https://convexityos.com/fundamentals/GRCE.md
- SEC CIK: 0001444192
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:02 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001444192&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Mar 31, 2026 |
| Operating Income | FY 2026 | -$23.67M | Operating profit |
| Net Income | FY 2026 | -$21.41M | GAAP bottom line |
| Diluted EPS | FY 2026 | -$1.06 | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $21.31M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | -- | $100.0M | $196K | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | $0 | $76K | -- | -- |
| **Gross Profit** | -- | -- | -- | -- | $100.0M | $120K | -- | -- |
| Research & Development | $2.40M | $9.51M | $4.68M | $9.97M | $5.56M | $4.17M | $15.97M | $29.37M |
| Selling, General & Admin | -- | -- | $6.94M | $8.28M | $9.78M | $6.66M | $8.46M | $5.03M |
| **Operating Income** | -$11.08M | -$16.68M | -$12.85M | -$52.16M | -$15.59M | -$16.42M | -$24.44M | -$34.41M |
| **EBITDA** | -$11.07M | -$16.67M | -$12.84M | -$52.03M | -$15.59M | -$15.49M | -$22.12M | -$32.07M |
| Interest Income | $685K | $711K | $911K | $246K | $77K | $107K | $336K | $358K |
| Income Before Tax | -$9.49M | -$12.77M | -$14.69M | -$51.97M | -$10.47M | -$19.68M | -$25.51M | -$39.37M |
| Income Tax Expense | -$1.70M | -$3.20M | -$1.83M | -$9.54M | -$648K | $0 | $0 | $0 |
| **Net Income** | -$7.79M | -$9.57M | -$12.85M | -$42.43M | -$9.82M | -$19.68M | -$25.51M | -$39.37M |
| Basic EPS | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$1.62 | -$7.98 | -$1.80 | -$4.38 |
| **Diluted EPS** | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$1.62 | -$7.98 | -$1.80 | -$4.38 |
| Basic Shares Outstanding | 16.5M | 12.1M | 9.5M | 7.4M | 6.1M | 2.5M | 14.1M | 9.1M |
| Diluted Shares Outstanding | 16.5M | 12.1M | 9.5M | 7.4M | 6.1M | 2.5M | 14.1M | 9.1M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $885K | $697K | $420K | $462K | $568K | $955K | $1.63M | $2.19M |
| **Operating Income** | -$2.29M | -$15.92M | -$3.01M | -$2.45M | -$2.53M | -$3.09M | -$3.18M | -$3.70M |
| **EBITDA** | -$2.29M | -$15.91M | -$3.01M | -$2.45M | -$2.53M | -$3.09M | -$3.18M | -$3.70M |
| Interest Income | $154K | $141K | $138K | $170K | $172K | $205K | $167K | $138K |
| Income Before Tax | -$2.14M | -$15.79M | -$2.88M | -$2.31M | -$938K | -$3.36M | -$382K | -$4.76M |
| Income Tax Expense | -$8.0K | $0 | -$1.70M | $0 | $0 | $0 | -$1.02M | -$605K |
| **Net Income** | -$2.13M | -$15.79M | -$1.18M | -$2.31M | -$938K | -$3.36M | $636K | -$4.16M |
| Basic EPS | -$0.11 | -$0.91 | -- | -$0.14 | -$0.06 | -$0.21 | -- | -$0.36 |
| **Diluted EPS** | -$0.11 | -$0.91 | -- | -$0.14 | -$0.06 | -$0.21 | -- | -$0.36 |
| Basic Shares Outstanding | 20.1M | 17.3M | -- | 16.9M | 15.9M | 15.9M | -- | 11.5M |
| Diluted Shares Outstanding | 20.1M | 17.3M | -- | 16.9M | 15.9M | 15.9M | -- | 11.5M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $16.98M | $22.13M | $23.00M | $27.88M | $30.34M | $50.94M | $14.24M | $16.87M |
| Short-Term Investments | -- | -- | $0 | $15K | $13.32M | $9.79M | -- | $8.89M |
| **Cash & Short-Term Investments** | $16.98M | $22.13M | $23.00M | $27.89M | $43.66M | $60.70M | $14.24M | $25.76M |
| Accounts Receivable, Net | -- | -- | $722K | $802K | $548K | $530K | $546K | $1.19M |
| Other Current Assets | -- | -- | -- | -- | -- | -- | $195K | $49K |
| **Total Current Assets** | $17.38M | $22.71M | $24.01M | $29.29M | $45.28M | $62.37M | $18.46M | $27.97M |
| Property, Plant & Equipment, Net | $8.0K | $15K | $24K | $104K | $20.89M | -- | $1.91M | $2.11M |
| Goodwill | $8.14M | $8.14M | $8.14M | $8.14M | $12.96M | -- | -- | -- |
| Intangible Assets | $41.13M | $41.13M | $41.13M | $41.13M | $69.81M | $0 | $4.24M | $6.39M |
| Long-Term Investments | -- | -- | -- | -- | -- | -- | -- | $20K |
| Other Non-Current Assets | -- | -- | -- | -- | -- | -- | $473K | $417K |
| **Total Non-Current Assets** | $49.27M | $49.28M | $49.29M | $49.83M | $83.34M | $86K | $4.39M | $8.93M |
| **Total Assets** | $66.65M | $71.99M | $73.30M | $79.12M | $128.6M | $62.46M | $22.85M | $36.90M |
| Accounts Payable | $702K | $601K | $1.01M | $1.24M | $1.68M | $115K | $1.71M | $3.05M |
| **Total Current Liabilities** | $2.15M | $1.93M | $1.68M | $3.41M | $3.26M | $1.58M | $7.39M | $13.67M |
| **Total Non-Current Liabilities** | $612K | $3.45M | $9.87M | $7.76M | $17.09M | $5.22M | $2.46M | $12.18M |
| **Total Liabilities** | $2.76M | $5.38M | $11.56M | $11.17M | $20.35M | $6.80M | $9.86M | $25.85M |
| **Total Debt (incl. Leases)** | -- | -- | -- | $485K | $295K | $86K | $147K | -- |
| Common Stock | $1.0K | $1.0K | $1.0K | $258.3M | $258.0M | $197.2M | $137.4M | $110.9M |
| Retained Earnings | -$228.5M | -$220.7M | -$211.1M | -$198.3M | -$155.8M | -$146.0M | -$126.3M | -$100.8M |
| Accumulated Other Comp. Income | -$6.04M | -$6.04M | -$6.04M | -$6.04M | -$6.04M | -$6.33M | -$7.89M | -$7.13M |
| **Total Stockholders' Equity** | $63.90M | $66.61M | $61.74M | $67.95M | $108.3M | $55.66M | $12.99M | $11.04M |
| Total Equity | $63.90M | $66.61M | $61.74M | $67.95M | $108.3M | $55.66M | $12.99M | $11.04M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $21.31M | $13.76M | $16.98M | $18.67M | $16.86M | $20.00M | $22.13M | $11.05M |
| **Cash & Short-Term Investments** | $21.31M | $13.76M | $16.98M | $18.67M | $16.86M | $20.00M | $22.13M | $11.05M |
| **Total Current Assets** | $21.96M | $14.33M | $17.38M | $19.21M | $17.30M | $20.52M | $22.71M | $11.94M |
| Property, Plant & Equipment, Net | -- | -- | $8.0K | -- | -- | -- | $15K | -- |
| Goodwill | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M |
| Intangible Assets | $27.59M | $27.59M | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M |
| **Total Non-Current Assets** | $35.74M | $35.74M | $49.27M | $49.28M | $49.28M | $49.28M | $49.28M | $49.28M |
| **Total Assets** | $57.70M | $50.07M | $66.65M | $68.49M | $66.58M | $69.81M | $71.99M | $61.22M |
| Accounts Payable | $410K | $408K | $702K | $114K | $459K | $1.34M | $601K | $665K |
| **Total Current Liabilities** | $1.61M | $1.25M | $2.15M | $1.28M | $1.25M | $2.31M | $1.93M | $1.97M |
| **Total Non-Current Liabilities** | $604K | $612K | $612K | $2.31M | $2.51M | $3.94M | $3.45M | $7.11M |
| **Total Liabilities** | $2.22M | $1.86M | $2.76M | $3.60M | $3.76M | $6.25M | $5.38M | $9.09M |
| Common Stock | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K |
| Retained Earnings | -$246.4M | -$244.3M | -$228.5M | -$227.3M | -$225.0M | -$224.0M | -$220.7M | -$221.3M |
| Accumulated Other Comp. Income | -$6.04M | -$6.04M | -$6.04M | -$6.04M | -$6.04M | -$6.04M | -$6.04M | -$6.04M |
| **Total Stockholders' Equity** | $55.48M | $48.21M | $63.90M | $64.89M | $62.82M | $63.55M | $66.61M | $52.14M |
| Total Equity | $55.48M | $48.21M | $63.90M | $64.89M | $62.82M | $63.55M | $66.61M | $52.14M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$7.79M | -$9.57M | -$12.85M | -$42.43M | -$9.82M | -$19.68M | -$25.51M | -$39.37M |
| Depreciation & Amortization | $7.0K | $7.0K | $11K | $124K | $0 | $924K | $2.32M | $2.33M |
| Stock-Based Compensation | $798K | $730K | $913K | $1.81M | $1.34M | $1.17M | $1.95M | -- |
| Change in Receivables | $106K | $596K | $80K | -$302K | $18K | -$58K | $581K | -$620K |
| Change in Payables | $543K | -$84K | -$1.65M | $411K | -- | -- | -- | -- |
| **Operating Cash Flow** | -$8.87M | -$14.90M | -$12.33M | -$15.91M | -$17.23M | -$14.32M | -$22.95M | -- |
| **Investing Cash Flow** | $0 | $0 | $104K | $13.15M | -$3.52M | -$9.86M | $8.14M | -- |
| Common Stock Issued | -- | -- | $0 | $304K | $0 | $59.33M | $6.98M | -- |
| **Financing Cash Flow** | $3.71M | $14.03M | $7.36M | $304K | $0 | $59.49M | $13.18M | -- |
| **Net Change in Cash** | -$5.16M | -$872K | -$4.87M | -$2.46M | -$20.60M | $36.70M | -$2.63M | -- |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$2.13M | -$15.79M | -$1.18M | -$2.31M | -$938K | -$3.36M | $636K | -$4.16M |
| Depreciation & Amortization | $1.0K | $2.0K | $2.0K | $3.0K | $0 | $2.0K | $2.0K | $2.0K |
| Stock-Based Compensation | $197K | $105K | $182K | $108K | $206K | $302K | $130K | $160K |
| Change in Receivables | $0 | $0 | $0 | $0 | $0 | $106K | $175K | $114K |
| Change in Payables | $229K | -$897K | $863K | $36K | -$1.07M | $711K | -$371K | -$703K |
| **Operating Cash Flow** | -$1.78M | -$3.22M | -$1.70M | -$2.23M | -$3.14M | -$1.80M | -$2.95M | -$4.12M |
| **Investing Cash Flow** | -- | -- | $0 | $0 | $0 | $0 | $0 | $15K |
| **Financing Cash Flow** | $9.34M | $0 | $0 | $4.04M | $0 | -$327K | $14.03M | $0 |
| **Net Change in Cash** | $7.55M | -$3.22M | -$1.70M | $1.81M | -$3.14M | -$2.13M | $11.08M | -$4.10M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gross Margin** | -- | -- | -- | -- | 100.0% | 61.2% | -- | -- |
| **Operating Margin** | -- | -- | -- | -- | -15.6% | -8377.0% | -- | -- |
| **Net Profit Margin** | -- | -- | -- | -- | -9.8% | -10039.8% | -- | -- |
| Return on Equity (ROE) | -12.2% | -14.4% | -20.8% | -62.4% | -9.1% | -35.4% | -196.3% | -356.4% |
| Return on Assets (ROA) | -11.7% | -13.3% | -17.5% | -53.6% | -7.6% | -31.5% | -111.6% | -106.7% |
| Current Ratio | 8.10x | 11.77x | 14.26x | 8.59x | 13.89x | 39.50x | 2.50x | 2.05x |
| Quick Ratio | 7.91x | 11.47x | 14.09x | 8.41x | 13.56x | 38.78x | 2.00x | 1.97x |
| Debt to Equity | -- | -- | -- | 0.01x | 0.00x | 0.00x | 0.01x | -- |
| **Revenue Growth (YoY)** | -- | -- | -- | -- | +50920.4% | -- | -- | -- |
| Gross Profit Growth (YoY) | -- | -- | -- | -- | +83233.3% | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -38.6% | -41.9% | -12.2% | -9.2% | -12.4% | -16.2% | -14.4% | -25.6% |
| Return on Assets (ROA) | -37.1% | -40.4% | -11.7% | -8.7% | -11.7% | -14.8% | -13.3% | -21.8% |
| Current Ratio | 13.61x | 11.47x | 8.10x | 14.96x | 13.89x | 8.87x | 11.77x | 6.06x |
| Quick Ratio | 13.20x | 11.00x | 7.91x | 14.54x | 13.54x | 8.64x | 11.47x | 5.61x |
| **Net Income Growth (YoY)** | -- | -- | -285.2% | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
